Shanghai Haohai Biological Technology Co (HKSE:06826) Total Liabilities : HK$1,163 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Total Liabilities?

Shanghai Haohai Biological Technology Co's Total Liabilities for the quarter that ended in Mar. 2024 was HK$1,163 Mil.

Shanghai Haohai Biological Technology Co's quarterly Total Liabilities increased from Sep. 2023 (HK$1,084.58 Mil) to Dec. 2023 (HK$1,190.26 Mil) but then declined from Dec. 2023 (HK$1,190.26 Mil) to Mar. 2024 (HK$1,163.13 Mil).

Shanghai Haohai Biological Technology Co's annual Total Liabilities increased from Dec. 2021 (HK$1,089.86 Mil) to Dec. 2022 (HK$1,105.57 Mil) and increased from Dec. 2022 (HK$1,105.57 Mil) to Dec. 2023 (HK$1,190.26 Mil).

Shanghai Haohai Biological Technology Co Total Liabilities Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Total Liabilities Chart

Shanghai Haohai Biological Technology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

554.73

669.13

1,089.86

1,105.57

1,190.26

Shanghai Haohai Biological Technology Co Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															-	1,272.72	1,084.58	1,190.26	1,163.13

Shanghai Haohai Biological Technology Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shanghai Haohai Biological Technology Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	783.092	+	(209.266	+	197.897
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,190

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	7771.843	-	6581.588
	=	1,190

Shanghai Haohai Biological Technology Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	749.293	+	(220.326	+	193.507
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,163

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	7813.715	-	6650.59
	=	1,163

Shanghai Haohai Biological Technology Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

688366:China

Address

No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN

Website

https://www.3healthcare.com

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines